logo.png
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
28 nov. 2022 08h00 HE | Enlivex Therapeutics Ltd
IND filing followed encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra™ was...
logo.png
Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
15 nov. 2022 08h00 HE | Enlivex Therapeutics Ltd
Multi-center trial of AllocetraTM in advanced solid tumor patientsAllocetraTM is administered to the patients either intravenously or locally, depending upon tumor locations, as both monotherapy and...
logo.png
Enlivex to Present at the 37th Annual Meeting of the Society For Immunotherapy Of Cancer
10 nov. 2022 08h00 HE | Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced a...
logo.png
Enlivex to Present at the 4th Macrophage-Directed Therapies Summit
03 oct. 2022 08h13 HE | Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
logo.png
Enlivex to Present at Upcoming Investor and Media Conferences
13 sept. 2022 08h00 HE | Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
logo.png
Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022
12 sept. 2022 08h00 HE | Enlivex Therapeutics Ltd
Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the deadliest solid cancers Combining cisplatin with Allocetra™ led to a...
logo.png
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy
06 sept. 2022 08h00 HE | Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
logo.png
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells
29 août 2022 08h00 HE | Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
logo.png
Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial
24 août 2022 08h00 HE | Enlivex Therapeutics Ltd
Sepsis Phase II protocol amendments have been cleared by regulatory authorities in Israel, Spain, and Greece. In addition to these clearances, Enlivex plans to obtain clearances for these protocol...
logo.png
Enlivex Announces Second Quarter 2022 Financial Results and Provides a Business Update
22 août 2022 08h00 HE | Enlivex Therapeutics Ltd
Dosed first patient in Phase I/II trial evaluating Allocetra™ combined with chemotherapy in patients with peritoneal metastases arising from solid cancersReceived Israeli Ministry of Health approval...